摘要
目的研究曲美他嗪治疗缺血性心肌病心力衰竭的临床疗效。方法选择72例缺血性心肌病患者,随机分为治疗组和对照组各36例,治疗组在常规治疗心力衰竭的基础上加曲美他嗪30mg,每日3次口服。对照组常规应用抗心力衰竭治疗,疗程为3个月,观察两组治疗前后左心室收缩末期内径(ESD)、舒张末期内径(EDD)、收缩末期容积(ESV)、舒张末期容积(EDV)、短轴缩短分数(FS)、每搏量(SV)、左心室射血分数(LVEF)、6 min步行距离。结果治疗组与对照组均能有效地治疗缺血性心肌病心力衰竭,两组治疗前后的自身比较显示ESV、FS、SV和LVEF均有统计学意义(P<0.05);治疗前两组比较差异无统计学意义;经过3个月的治疗后,组间比较显示治疗组的ESD、ESV、FS、SV和LVEF较对照组有进一步的改善(P<0.05),两组均未发现与药物相关的不良反应。结论曲美他嗪能有效改善缺血性心肌病患者的心功能,值得临床推广应用。
Objective To analyze the clinical therapeutic effect of trimetazidine in reatment of heart failure of ischemic cardiomyopathy.Methods 72 patients with ischemic cardiomyopathy were randomly divided into treatment group and control group,36 cases in each group.The control group received conventional anti-heart failure therapy,the treatment group received trimetazidine 30 mg ovally,3 times each day,based on conventional anti-heart failure therapy,the course of treatment was 3months.We examined left ventricular end systolic diameter（ESD）,left ventricular enddiastolic diameter（EDD）,left ventricular end systolic volume（ESV）,left ventricular enddiastolic volume（EDV）,fractional shortening（FS）,stroke volume（SV）,left ventricular eject fraction（LVEF）and 6-minute walking distance of two groups before and after treatment.Results The treatment of two groups were both effective on heart failure of ischemic cardiomyopathy.There were significant differences of ESV,FS,SV and LVEF in both groups before and after treatment（P〈0.05）.ESD,ESV,FS,SV and LVEF in treatment group were significantly better than in control group 3 months after treatment（P〈0.05）.No drug-related adverse reactions were found in both groups.Conclusion Trimetazidine can effectively improve heart function of patients with ischemic cardiomyopathy,and is worthy of clinical application.
出处
《医学综述》
2012年第3期469-471,共3页
Medical Recapitulate
关键词
曲美他嗪
缺血性心肌病
心力衰竭
Trimetazidine
Ischemic cardiomyopathy
Heart failure
